The long range goals of this project are to determine whether the vaccination of HIV-1-seronegative and seropositive human volunteers with candidate AIDS vaccines results in the generation of HIV-1-specific cytolytic T lymphocyte (CTL) responses, to analyze individual variation in the strength and duration of vaccine-induced CTL responses, and to examine important functional aspects of the CTL response at clonal level. We have previously shown that seronegative volunteers immunized with HIV-1 envelope protein subunit vaccines develop CD4+, MHC class II-restricted CTL that lyse HIV-1-infected cells in rapid, efficient, and highly specific fashion. In addition, we have recently found that individuals vaccinated with live vaccinia virus carrying the HIV-1 env gene have an extremely high level of CD8+, class I-restricted CTL activity specific for the HIV-1 envelope protein. In the proposed studies, both MHC class I- and class II-restricted CTL responses will be analyzed in human volunteers participating in all current and future NIAID-sponsored Phase I AIDS vaccine clinical trials. Assays to detect both active circulating CTL and resting memory CTL will be used. We will compare the ability of various vaccines to induce class I- and class II- restricted CTL and determine the duration of the memory response for each type of CTL. HIV-1-specific CTL clones will be isolated from vaccine recipients at multiple time points during the trials. The availability of stable, long term T cell clones will permit us to characterize in detail important parameters of vaccine-induced CTL response including phenotype, HLA restriction, epitopes recognized, cross-reactivity with various strains, and cytokines produced. Studies with CTL clones will focus on properties likely to influence ability of vaccine-induced clones to control the spread of HIV-1 infection in vivo such as capacity to lyse HIV-1-infected cells and secretion of cytokines such as TNF-alpha that upregulate HIV-1 gene expression. Finally, because class II-restricted CTL may play an important role in vaccine- induced immune response by virtue of their ability to destroy infected cells and to downregulate specific antibody responses, we will attempt to define molecular markers for the subset of CD4+ T cells with cytolytic activity and to analyze key aspects of the CD4+ CTL response, including the ontogeny of CD4+ CTL, the antigen receptor repertoire of these cells, their trafficking patterns, their role in regulation of B cell responses, and mechanism of cytolysis by these CTL.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
1R01AI032871-01
Application #
3147939
Study Section
AIDS and Related Research Study Section 1 (ARRA)
Project Start
1992-05-15
Project End
1997-04-30
Budget Start
1992-05-15
Budget End
1993-04-30
Support Year
1
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
Schools of Medicine
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Ferris, R L; Hall, C; Sipsas, N V et al. (1999) Processing of HIV-1 envelope glycoprotein for class I-restricted recognition: dependence on TAP1/2 and mechanisms for cytosolic localization. J Immunol 162:1324-32
Ray, S C; Lubaki, N; Dhruva, B R et al. (1998) Autologous strain-specific cytolytic T lymphocyte responses directed against human immunodeficiency virus type 1 Env. AIDS Res Hum Retroviruses 14:3-13
McElrath, M J; Siliciano, R F; Weinhold, K J (1997) HIV type 1 vaccine-induced cytotoxic T cell responses in phase I clinical trials: detection, characterization, and quantitation. AIDS Res Hum Retroviruses 13:211-6
Lubaki, N M; Ray, S C; Dhruva, B et al. (1997) Characterization of a polyclonal cytolytic T lymphocyte response to human immunodeficiency virus in persons without clinical progression. J Infect Dis 175:1360-7
Liu, A Y; Torchia, B S; Migeon, B R et al. (1997) The human NTT gene: identification of a novel 17-kb noncoding nuclear RNA expressed in activated CD4+ T cells. Genomics 39:171-84
Ferris, R L; Buck, C; Hammond, S A et al. (1996) Class I-restricted presentation of an HIV-1 gp41 epitope containing an N-linked glycosylation site. Implications for the mechanism of processing of viral envelope proteins. J Immunol 156:834-40
Hammond, S A; Johnson, R P; Kalams, S A et al. (1995) An epitope-selective, transporter associated with antigen presentation (TAP)-1/2-independent pathway and a more general TAP-1/2-dependent antigen-processing pathway allow recognition of the HIV-1 envelope glycoprotein by CD8+ CTL. J Immunol 154:6140-56
Egan, M A; Pavlat, W A; Tartaglia, J et al. (1995) Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene. J Infect Dis 171:1623-7
Miskovsky, E P; Liu, A Y; Pavlat, W et al. (1994) Studies of the mechanism of cytolysis by HIV-1-specific CD4+ human CTL clones induced by candidate AIDS vaccines. J Immunol 153:2787-99
Lubaki, M N; Egan, M A; Siliciano, R F et al. (1994) A novel method for detection and ex vivo expansion of HIV type 1-specific cytolytic T lymphocytes. AIDS Res Hum Retroviruses 10:1427-31

Showing the most recent 10 out of 13 publications